Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH

Completed · Phase 4

Conditions studied: Kidney Diseases

In brief

FSGS is an immunologic disorder wherein circulating immune proteins cause damage to the kidneys and progressive injury and scarring. Corticosteroid therapy is occasionally, but not nearly universally, successful in reducing proteinuria, and when patients respond, they have a favorable prognosis. The investigators believe that ACTH therapy (H.P. Acthar Gel) can provide a more rapid, well tolerated reduction in glomerular injury.

Key facts

Study ID
NCT01155141
Run by
Stanford University
People needed
15
Starts
2009-09-01
Expected to finish
2014-01-01
Last updated by the study team
2014-09-01

Who can join

Age: 16 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.